Form 4: Teva Director Converts RSUs to Ordinary Shares

Teva Pharmaceutical Industries Director Chen Lichtenstein converted 4,804 restricted share units into ordinary shares on December 2, 2025.

Summary

• Director Chen Lichtenstein of Teva Pharmaceutical Industries Ltd. converted 4,804 Restricted Share Units (RSUs) into Ordinary Shares.
• The transaction occurred on December 2, 2025, coinciding with the vesting date of the RSUs, which were granted on December 2, 2024.
• Following this conversion, the director directly beneficially owns 4,804 Ordinary Shares.
• Each RSU represents a contingent right to receive one ordinary share or its cash value at settlement, at the option of the Human Resources and Compensation Committee.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine disclosure of compensation realization for a director, indicating a planned event. It does not present new information that would significantly alter the company's outlook or valuation.

Positives

• Director Chen Lichtenstein realized compensation through the vesting and conversion of 4,804 Restricted Share Units into Ordinary Shares.

Future Outlook

The filing is a disclosure of a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing reflects a routine compensation event for a director at a major pharmaceutical company. Such transactions are common for executives and directors receiving equity-based compensation as part of their remuneration packages.

Stakeholder Impact

• Shareholders: Minor dilution from the issuance of new shares (if applicable, depending on whether shares are newly issued or from treasury stock).
• Director (Chen Lichtenstein): Realization of equity compensation, increasing direct ownership in the company.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned conversion of Restricted Share Units (RSUs) into ordinary shares by a director as part of their compensation. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected event and does not indicate any significant positive or negative catalysts for the stock.

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Restricted Share Units, RSU conversion, Director compensation, Chen Lichtenstein, Ordinary Shares